Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, NY, November 27, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December.
Funding the next wave of biopharma innovation
Our firm
We operate at the intersection of science, medicine and investing
We are the world’s largest buyer of biopharmaceutical royalties and a leading funder of innovation in life sciences.
Learn more
#1
Buyer of biopharma royalties
>$30bn
Announced transactions since founding
>80
Royalty acquisitions since founding
Partners
Partner with us
We are the leading partner funding innovation in life sciences with more than 60% global market share. Our unique capabilities to provide tailored funding solutions and customize win-win partnerships have positioned us as the partner of choice in the biopharma ecosystem.
Learn more about Royalty Pharma
Investors
Inaugural Investor Day
Royalty Pharma Investor Day highlights stronger growth outlook and the power of its unique business model to do drive value for all stakeholders.
Stock information
RPRX
${{TradePrice}}
{{TradeDate}}
Latest quarterly earnings
Q3 2024
News
Latest developments
Royalty Pharma Announces Inaugural Prize For Impact In Healthcare
NEW YORK, NY, November 14, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient’s work.
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
NEW YORK, NY, November 7, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO for $125 million in cash upfront.
Royalty Pharma Reports Third Quarter 2024 Results
NEW YORK, NY, November 6, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.
Responsibility
Creating value for stakeholders
We create value for our stakeholders by funding innovation across the life sciences ecosystem. Our policies and practices are designed to minimize our sustainability-related risk and uphold our commitments to our stakeholders and partners.
Accelerating Bio-Innovation
At the leading edge of life sciences
Held in partnership with the University of Cambridge and the Massachusetts Institute of Technology since 2019, the Accelerating Bio-Innovation Conference is an interdisciplinary summit that brings to light the triumphs and hurdles in drug discovery and development. The event brings together thought leaders from the bio-innovation sphere to engage in crucial debates and discussions confronting pioneers in the world of new biopharmaceuticals, bridging the realms of science, investing and innovative therapeutics.
Find out more
